Indication: Non-Small Cell Lung Cancer (NSCLC)
A PHASE 2 STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD PRIOR DISEASE PROGRESSION ON A PD-1/L-1 INHIBITOR
Sub-indication: Lung Cancer
Study Type: Drug Study
Principal Investigator: Adam Lye, M.D.Norton Cancer Institute
Sponsor: Sponsor: BioAtla LLC
Learn more at ClinicalTrials.gov
Email for more information: Lung-NCIResearch@nortonhealthcare.org